[go: up one dir, main page]

DE69736838D1 - Herpesvirus saimiri als viraler vektor - Google Patents

Herpesvirus saimiri als viraler vektor

Info

Publication number
DE69736838D1
DE69736838D1 DE69736838T DE69736838T DE69736838D1 DE 69736838 D1 DE69736838 D1 DE 69736838D1 DE 69736838 T DE69736838 T DE 69736838T DE 69736838 T DE69736838 T DE 69736838T DE 69736838 D1 DE69736838 D1 DE 69736838D1
Authority
DE
Germany
Prior art keywords
herpesvirus saimiri
viral vector
genes
essential
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69736838T
Other languages
English (en)
Other versions
DE69736838T2 (de
Inventor
Mark Meredith
Fred Markham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Leeds
Original Assignee
University of Leeds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Leeds filed Critical University of Leeds
Application granted granted Critical
Publication of DE69736838D1 publication Critical patent/DE69736838D1/de
Publication of DE69736838T2 publication Critical patent/DE69736838T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16411—Rhadinovirus, e.g. human herpesvirus 8
    • C12N2710/16422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16411—Rhadinovirus, e.g. human herpesvirus 8
    • C12N2710/16441—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69736838T 1996-09-04 1997-09-04 Herpesvirus saimiri als viraler vektor Expired - Fee Related DE69736838T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9618477 1996-09-04
GBGB9618477.5A GB9618477D0 (en) 1996-09-04 1996-09-04 Gene therapy
PCT/GB1997/002371 WO1998010083A1 (en) 1996-09-04 1997-09-04 Herpesvirus saimiri as viral vector

Publications (2)

Publication Number Publication Date
DE69736838D1 true DE69736838D1 (de) 2006-11-30
DE69736838T2 DE69736838T2 (de) 2007-10-31

Family

ID=10799414

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69736838T Expired - Fee Related DE69736838T2 (de) 1996-09-04 1997-09-04 Herpesvirus saimiri als viraler vektor

Country Status (18)

Country Link
US (1) US6379967B1 (de)
EP (1) EP0939828B1 (de)
JP (1) JP2000517191A (de)
KR (1) KR20000068461A (de)
CN (1) CN1237209A (de)
AT (1) ATE342997T1 (de)
AU (1) AU737197B2 (de)
BR (1) BR9711998A (de)
CA (1) CA2264956A1 (de)
CZ (1) CZ69799A3 (de)
DE (1) DE69736838T2 (de)
ES (1) ES2274541T3 (de)
GB (1) GB9618477D0 (de)
HU (1) HUP9904329A3 (de)
IL (1) IL128635A0 (de)
NZ (1) NZ334323A (de)
SG (1) SG91252A1 (de)
WO (1) WO1998010083A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826069D0 (en) * 1998-11-28 1999-01-20 Univ Leeds HIV vaccine
GB9903694D0 (en) * 1999-02-19 1999-04-14 Univ Leeds Latency-associated regulatory region
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20040219516A1 (en) * 2002-07-18 2004-11-04 Invitrogen Corporation Viral vectors containing recombination sites
EP2484687A3 (de) 2003-08-08 2012-11-14 Life Technologies Corporation Verfahren und Zusammensetzungen zum nahtlosen Klonieren von Nukleinsäuremolekülen
ATE469984T1 (de) 2003-12-01 2010-06-15 Life Technologies Corp Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
RU2423381C2 (ru) 2005-07-25 2011-07-10 Трабьон Фармасьютикалз, Инк. Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
BRPI0814060A2 (pt) * 2007-07-06 2015-01-06 Trubion Pharmaceuticals Inc Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal
EP2132228B1 (de) * 2008-04-11 2011-06-22 Emergent Product Development Seattle, LLC Cd37-immuntherapeutikum und kombination mit bifunktionellem chemotherapeutikum davon
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
US11149255B2 (en) * 2016-09-06 2021-10-19 Bioventures, Llc Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors
CN107653345B (zh) * 2017-11-08 2021-04-27 中国人民解放军军事医学科学院野战输血研究所 猴b病毒实时荧光定量pcr方法及其通用引物、mgb探针与试剂盒
RU2771081C2 (ru) * 2020-08-25 2022-04-26 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Рекомбинантный штамм Herpesvirus saimiri для получения популяций иммортализованных аутологичных Т-лимфоцитов, экспрессирующих парные химерные рецепторы против опухолевых антигенов CD44 и CD133

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672344A (en) * 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
JPH04503300A (ja) * 1988-10-06 1992-06-18 デイナ・フアーバー・キヤンサー・インステイテユート Ｈ．ｓａｉｍｉｒｉ―ｈｔｌｖ―ｘ領域ベクター
DE3834157A1 (de) * 1988-10-07 1990-04-19 Behringwerke Ag Selektionierbare vektoren fuer humane t-zellen

Also Published As

Publication number Publication date
WO1998010083A1 (en) 1998-03-12
HUP9904329A2 (hu) 2000-04-28
KR20000068461A (ko) 2000-11-25
DE69736838T2 (de) 2007-10-31
JP2000517191A (ja) 2000-12-26
CN1237209A (zh) 1999-12-01
BR9711998A (pt) 2000-01-18
EP0939828A1 (de) 1999-09-08
CZ69799A3 (cs) 1999-08-11
CA2264956A1 (en) 1998-03-12
HUP9904329A3 (en) 2002-01-28
IL128635A0 (en) 2000-01-31
NZ334323A (en) 2000-06-23
ES2274541T3 (es) 2007-05-16
GB9618477D0 (en) 1996-10-16
ATE342997T1 (de) 2006-11-15
AU4307197A (en) 1998-03-26
EP0939828B1 (de) 2006-10-18
AU737197B2 (en) 2001-08-09
SG91252A1 (en) 2002-09-17
US6379967B1 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
ATE342997T1 (de) Herpesvirus saimiri als viraler vektor
HK1018078A1 (en) Recombinant sendai virus
IL122120A (en) Recombinant mva virus containing a foreign gene inserted in a naturally occuring deletion within the genome
DE69230882D1 (de) Cytosindeaminase negatives selektionssystem zur genübertragung und therapien
DK0500917T3 (da) Vacciner og fremgangsmåder baseret på rekombinante herpes simplex virusser.
MX9702553A (es) Adenovirus libres de particulas contaminantes viables, su preparacion y su uso.
FI973309A0 (fi) Menetelmä yhdistelmä-DNA-adenovirusgenomin valmistamiseksi
IL181695A0 (en) Methods for cultivating cells and propagating viruses
DE69730153D1 (de) EHV-1 Vektoren
MX9707910A (es) Vector viral recombinante inducible por la glucosa.
ATE226638T1 (de) Retroviraler vektor und dessen verwendung in gentherapie
ATE178654T1 (de) Impstoff zum schutze von pferden gegen pferdeherpesvirus-infektionen
HUP9902585A2 (hu) Replikálódó molekulák in vivo előállítása
KR100569826B1 (ko) 컴팩트한 엡스타인-바 바이러스 레플리콘
Green et al. Endogenous ecotropic and recombinant MCF mouse retroviral variation and escape from antiviral CTL
EP1015560A4 (de) Veränderte, kleine rna-viren
MY157873A (en) Recombinant mva virus, and the use thereof
MY134484A (en) Recombinant mva virus, and the use thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee